Tango Therapeutics, Inc. Research and Development Expense
Tango Therapeutics, Inc. (TNGX) reported Research and Development Expense of $37.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Tango Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $37.20M, a 13.39% increase year-over-year.
- Tango Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $33.53M, a 7.98% decline year-over-year.
- Tango Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $32.10M, a 5.41% decline year-over-year.
- Tango Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $30.82M, a 7.36% decline year-over-year.
- Tango Therapeutics, Inc. research and development expense for fiscal 2025 was $132.16M, a 8.17% decline from fiscal 2024.
- Tango Therapeutics, Inc. research and development expense for fiscal 2024 was $143.92M, a 24.93% increase from fiscal 2023.
- Tango Therapeutics, Inc. research and development expense for fiscal 2023 was $115.20M, a 8.77% increase from fiscal 2022.
- Tango Therapeutics, Inc. research and development expense for fiscal 2022 was $105.91M, a 36.41% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.20M 10-Q · filed 2026-08-11 | $70.73M 10-Q · filed 2026-08-11 | $102.83M derived: sum of 3 quarters · filed 2026-08-11 | $133.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $33.53M 10-Q · filed 2026-05-13 | $65.64M derived: sum of 2 quarters · filed 2026-05-13 | $96.45M derived: sum of 3 quarters · filed 2026-05-13 | $129.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $32.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $62.92M derived: sum of 2 quarters · filed 2026-03-05 | $95.72M derived: sum of 3 quarters · filed 2026-08-11 | $132.16M 10-K · filed 2026-03-05 |
| 2025-09-30 | $30.82M 10-Q · filed 2025-11-04 | $63.62M derived: sum of 2 quarters · filed 2026-08-11 | $100.06M 10-Q · filed 2025-11-04 | $134.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $32.81M 10-Q · filed 2026-08-11 | $69.25M 10-Q · filed 2026-08-11 | $103.19M derived: sum of 3 quarters · filed 2026-08-11 | $136.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $36.44M 10-Q · filed 2026-05-13 | $70.38M derived: sum of 2 quarters · filed 2026-05-13 | $103.64M derived: sum of 3 quarters · filed 2026-05-13 | $142.30M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $33.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $67.20M derived: sum of 2 quarters · filed 2026-03-05 | $105.85M derived: sum of 3 quarters · filed 2026-03-05 | $143.92M 10-K · filed 2026-03-05 |
| 2024-09-30 | $33.26M 10-Q · filed 2025-11-04 | $71.92M derived: sum of 2 quarters · filed 2025-11-04 | $109.98M 10-Q · filed 2025-11-04 | $141.32M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $38.65M 10-Q · filed 2025-08-05 | $76.72M 10-Q · filed 2025-08-05 | $108.06M derived: sum of 3 quarters · filed 2026-03-05 | $135.21M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $38.06M 10-Q · filed 2025-05-12 | $69.40M derived: sum of 2 quarters · filed 2026-03-05 | $96.55M derived: sum of 3 quarters · filed 2026-03-05 | $125.22M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $31.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $58.49M derived: sum of 2 quarters · filed 2026-03-05 | $87.16M derived: sum of 3 quarters · filed 2026-03-05 | $115.20M 10-K · filed 2026-03-05 |
| 2023-09-30 | $27.15M 10-Q · filed 2024-11-06 | $55.82M derived: sum of 2 quarters · filed 2024-11-06 | $83.86M 10-Q · filed 2024-11-06 | $112.95M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $28.67M 10-Q · filed 2024-08-07 | $56.71M 10-Q · filed 2024-08-07 | $85.80M derived: sum of 3 quarters · filed 2025-02-27 | $114.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $28.04M 10-Q · filed 2024-05-08 | $57.13M derived: sum of 2 quarters · filed 2025-02-27 | $85.87M derived: sum of 3 quarters · filed 2025-02-27 | $109.61M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $29.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $57.84M derived: sum of 2 quarters · filed 2025-02-27 | $81.58M derived: sum of 3 quarters · filed 2025-02-27 | $105.91M 10-K · filed 2025-02-27 |
| 2022-09-30 | $28.74M 10-Q · filed 2023-11-08 | $52.48M derived: sum of 2 quarters · filed 2023-11-08 | $76.81M 10-Q · filed 2023-11-08 | $98.45M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $23.74M 10-Q · filed 2023-08-07 | $48.07M 10-Q · filed 2023-08-07 | $69.70M derived: sum of 3 quarters · filed 2023-08-07 | $91.63M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $24.33M 10-Q · filed 2023-05-09 | $45.96M derived: sum of 2 quarters · filed 2023-05-09 | $67.89M derived: sum of 3 quarters · filed 2023-05-09 | $86.97M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $21.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $43.56M derived: sum of 2 quarters · filed 2023-03-27 | $62.64M derived: sum of 3 quarters · filed 2023-03-27 | $77.64M 10-K · filed 2023-03-27 |
| 2021-09-30 | $21.92M 10-Q · filed 2022-11-10 | $41.00M derived: sum of 2 quarters · filed 2022-11-10 | $56.00M 10-Q · filed 2022-11-10 | $71.06M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $19.08M 10-Q · filed 2022-08-10 | $34.08M 10-Q · filed 2022-08-10 | $49.14M derived: sum of 3 quarters · filed 2022-08-10 | $62.12M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $15.00M 10-Q · filed 2022-05-11 | $30.06M derived: sum of 2 quarters · filed 2022-05-11 | $43.04M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $15.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $28.04M derived: sum of 2 quarters · filed 2022-03-28 | $49.99M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $12.98M 10-Q · filed 2021-11-09 | $34.93M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |